Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: An overview

Mutation Research - Reviews in Mutation Research

Volumn 753, Issue 1, 2013, Pages 7-23

  Chaudhary, Ajay Kumar ^a   Pandya, Shruti ^b   Ghosh, Kanjaksha ^a   Nadkarni, Anita ^a  

^a NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Drug targets therapy; Hematological malignancies; MMPs; Polymorphism and solid cancer; SNPs

Indexed keywords

2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; AE 941; BATIMASTAT; BISPHOSPHONIC ACID DERIVATIVE; COLLAGENASE 3; GELATINASE A; GELATINASE B; INCYCLINIDE; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 18; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PEPTIDOMIMETIC AGENT; PRINOMASTAT; SOLIMASTAT; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CELL GROWTH; CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTOLOGY; DRUG BIOAVAILABILITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HEAD AND NECK CANCER; HEALTH CARE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TRANSCRIPTION REGULATION; TUMOR GROWTH; WESTERN BLOTTING; ZYMOGRAPHY;

DRUG TARGETS THERAPY; HEMATOLOGICAL MALIGNANCIES; MMPS; POLYMORPHISM AND SOLID CANCER; SNPS;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; NEOPLASMS;

EID: 84881237328     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2013.01.002     Document Type: Review

References (171)

1. John A., Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. 2001, 7:14-23.
2. Beaudeux J.L., Giral P., Bruckert E., et al. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin. Chem. Lab. Med. 2004, 42:121-131.
3. Chaudhary A.K., Singh M., Bharti A.C., et al. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. Biomed. Sci. 2010, 17:10.
4. Eisen A., Jeffrey J., Gross J. Human skin collagenase, Isolation and mechanism of attack on the collagen molecule. Biochim. Biophys. Acta 1968, 151:637-645.
5. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27:5287-5297.
6. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
7. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2:657-672.
8. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92:827-839.
9. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005, 87(3-4):249-263.
10. Jozic D., Bourenkov G., Lim N.H., et al. X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. J. Biol. Chem. 2005, 280(10):9578-9585.
11. Morgunova E., Tuuttila A., Bergmann U., et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999, 284(5420):1667-1670.
12. Murphy G., Nagase H. Progress in matrix metalloproteinase research. Mol. Aspects Med. 2008, 29(5):290-308.
13. Morrison C.J., Butler G.S., Rodríguez D., Overall C.M. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell Biol. 2009, 21(5):645-653.
14. Van den Steen P.E., Dubois B., et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 2002, 37:375-536.
15. Aimes R.T., Quigley J.P. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J. Biol. Chem. 1995, 270:5872-5876.
16. Patterson M.L., Atkinson S.J., et al. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett. 2001, 503:158-162.
17. Groft L.L., Muzik H., Rewcastle N.B., et al. Differential expression and localisation of TIMP-1 and TIMP-4 in human gliomas. Br. J. Cancer 2001, 85:55-63.
18. Tschesche H. Leukodiapedesis, function, and physiological role of leucocyte matrix metalloproteinases. Adv. Exp. Med. Biol. 1997, 421:285-301.
19. Hernandez-Barrantes S., Shimura Y., Soloway P.D., et al. Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem. Biophys. Res. Commun. 2001, 281:126-130.
20. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1104-1117.
21. Liu Z., Ivanoff A., Klominek J. Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int. J. Cancer 2001, 91:638-643.
22. Nikkola J., Vihinen P., Vlaykova T., et al. High expression levels of collagenases-1 and stromelysin-1 correlate with shorter disease free survival in human metastatic melanoma. Int. J. Cancer 2002, 97(4):432-438.
23. Pei D., Majmudar G., Weiss S.J. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem. 1994, 269:25849-25855.
24. Luo D., Mari B., Stoll I., Anglard P. Alternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinase. J. Biol. Chem. 2002, 277:25527-25536.
25. Van den Steen P.E., Proost P., Grillet B., et al. Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J. 2002, 16:379-389.
26. Ye S., Eriksson P., Hamsten A., et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 1996, 271:13055-13060.
27. Marchenko N.D., Marchenko G.N., Weinreb R.N., et al. Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int. J. Biochem. Cell Biol. 2004, 36:942-956.
28. Ohuchi E., Imai K., Fujii Y., et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 1997, 272:2446-2451.
29. Holmbeck K., Bianco P., Caterina J., et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
30. Vairaktaris E., Serefoglou Z., Yapijakis C., et al. High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res. 2007, 27:2493-2498.
31. Chaudhary A.K., Singh M., Bharti A.C., Singh M., Shukla S., Singh A.K., Mehrotra R. Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer 2010, 10:369.
32. Cao Z.G., Li C.Z. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population. Oral Oncol. 2006, 42:32-38.
33. Singh R.D., Haridas N., Patel J.B., et al. Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J. Clin. Biochem. 2010, 25:250-259.
34. Mäkinen L.K., Häyry V., Atula T., et al. Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. J. Oral Pathol. Med. 2012, 41:394-399.
35. Chaudhary A.K., Pandya S., Mehrotra R., et al. Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers 2011, 16:577-586.
36. Stott-Miller M., Houck J.R., Lohavanichbutr P., et al. Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2011, 20:2628-2636.
37. Luizon M.R., Almeida Belo V.D. Matrix metalloproteinase (MMP)-2 and MMP-9 polymorphisms and haplotypes as disease biomarkers. Biomarkers 2012, 17:286-288.
38. Stetler-Stevenson M., Mansoor A., Limet al M. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood 1997, 89:1708-1715.
39. Alexander C.M., Werb Z. Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro. J. Cell Biol. 1992, 118:727-739.
40. DeClerck Y.A., Perez N., Shimada H., et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992, 52:701-708.
41. Vu T.H., Shipley J.M., Bergers G., et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
42. Guedez L., Suresh A., Tung F., Zucali J. Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bcl-2. Eur. J. Haematol. 1996, 57:149-156.
43. Ries C., Loher F., Zang C., et al. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin. Cancer Res. 1999, 5:1115-1124.
44. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression. J. Cell. Physiol. 2007, 211:19-26.
45. Fanjul-Fernández M., Folgueras A.R., Cabrera S., López-Otín C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 2010, 1803:3-19.
46. Benbow U., Brinckerhoff C.E. The AP-1 site and MMP gene regulation: what is all the fuss about?. Matrix Biol. 1997, 15:519-526.
47. Chicoine E., Estève P.O., Robledo O., et al. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem. Biophys. Res. Commun. 2002, 297:765-772.
48. Shukeir N., Pakneshan P., Chen G., et al. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 2006, 66:9202-9210.
49. Kang T., Nagase H., Pei D. Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Cancer Res. 2002, 62:675-681.
50. Yana I., Weiss S.J. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol. Biol. Cell 2000, 11:2387-2401.
51. Sato H., Takino T., Okada Y., et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
52. Shamamian P., Schwartz J.D., Pocock B.J., et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J. Cell. Physiol. 2001, 189:197-206.
53. Herman M.P., Sukhova G.K., Kisiel W., et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest. 2001, 107:1117-1126.
54. Nakada M., Yamada A., Takino T., et al. Suppression of membrane-type 1 matrix metalloproteinase (MMP)-mediated MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-Tes. Cancer Res. 2001, 61:8896-8902.
55. Demeule M., Brossard M., Page M., et al. Matrix metalloproteinase inhibition by green tea catechins. Biochim. Biophys. Acta 2000, 1478:51-60.
56. Mix K.S., Mengshol J.A., Benbow U., et al. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. 2001, 44:1096-1104.
57. Bernardo M.M., Brown S., Li Z.H., et al. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J. Biol. Chem. 2002, 277:11201-11207.
58. Yu X.F., Han Z.C. Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol. Histopathol. 2006, 21:519-531.
59. Cheng T., Rodrigues N., Shen H., et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000, 287:1804-1808.
60. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2:737-744.
61. Ogawa M., Kawamoto M., Yamanaka N. Matrix metalloproteinase and tissue inhibitor of metalloproteinase in human bone marrow tissues-an immunohistochemical study. J. Nippon Med. Sch. 2000, 67:235-241.
62. Marquez-Curtis L.A., Dobrowsky A., Montano J., Turner A.R., Ratajczak J., Ratajczak M.Z., Janowska-Wieczorek A. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by hematopoietic and stromal precursors and their production in normal and leukemic long-term marrow cultures. Br. J. Haematol. 2001, 115:595-604.
63. Molica S., Vitelli G., Levato D., et al. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. Eur. J. Haematol. 2004, 73(1):36-42.
64. Buggins A.G., Levi A., Gohil S., et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br. J. Haematol. 2011, 154(2):216-266.
65. Travaglino E., Benatti C., Malcovati L., et al. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur. J. Haematol. 2008, 80:216-226.
66. Lane W.J., Dias S., Hattori K., et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood 2000, 96:4152-4159.
67. Majka M., Janowska-Wieczorek A., Ratajczak J., et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood 2000, 96:4142-4151.
68. Lapidot T., Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp. Hematol. 2002, 30:973-981.
69. Carstanjen D., Ulbricht N., Iacone A., et al. Matrix metalloproteinase-9 (gelatinase B) is elevated during mobilization of peripheral blood progenitor cells by G-CSF. Transfusion (Paris) 2002, 42:588-596.
70. Rao Q., Zheng G.G., Lin Y.M., Wu K.F. Production of matrix metalloproteinase-9 by cord blood CD34+ cells and its role in migration. Ann. Hematol. 2004, 83:409-413.
71. Zheng Y., Sun A., Han Z.C. Stem cell factor improves SCID-repopulating activity of human umbilical cord blood-derived hematopoietic stem/progenitor cells in xenotransplanted NOD/SCID mouse model. Bone Marrow Transplant. 2005, 35:137-142.
72. Hendrix M.J., Seftor E.A., Grogan T.M., et al. Expression of type IV collagenase correlates with the invasion of human lymphoblastoid cell lines and pathogenesis in SCID mice. Mol. Cell. Probes 1992, 6:59-65.
73. Kuittinen O., Savolainen E.R., Koistinen P., et al. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk. Res. 2001, 25:125-131.
74. Janowska-Wieczorek A., Marquez L.A., Nabholtz, et al. Growth factors and cytokines upregulate gelatinase expression in bone mar row CD34+ cells and their transmigration through reconstituted basement membrane. Blood 1999, 93:3379-3390.
75. Borregaard N., Sehested M., Nielsen B.S., et al. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood 1995, 85:812-817.
76. Devy L., Hollender P., Munaut C., et al. Matrix and serine protease expression during leukemic cell differentiation induced by aclacino-mycin and all-trans-retinoic acid. Biochem. Pharmacol. 2002, 63:179-189.
77. Peiretti F., Bernot D., Lopez S., et al. Modulation of PAI-1 and proMMP-9 syntheses by soluble TNF-alpha and its receptors during differentiation of the human monocytic HL-60 cell line. J. Cell. Physiol. 2003, 196:346-353.
78. Arimura K., Arima N., Matsushita K., et al. Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. Eur. J. Haematol. 2004, 73:17-24.
79. Suminoe A., Matsuzaki A., Hattori H., et al. Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk. Res. 2007, 31:1437-1440.
80. Schneider P., Costa O., Legrand E., et al. In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia. Leuk. Res. 2010, 34:24-31.
81. Casabonne D., Reina O., Benavente Y., et al. Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph. Haematologica 2011, 96:323-327.
82. Scrideli C.A., Cortez M.A., Yunes J.A., et al. mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leuk. Res. 2010, 34:32-37.
83. Dutta A., Sen T., Chatterjee A. Culture of K562 human myeloid leukemia cells in presence of fibronectin expresses and secretes MMP-9 in serum-free culture medium. Int. J. Clin. Exp. Pathol. 2010, 3:288-302.
84. Iwata M., Pillai M., Ramakrishnan A., et al. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. Blood 2007, 109:85-92.
85. Lin L.I., Lin D.T., Chang C.J., et al. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br. J. Haematol. 2002, 117:835-841.
86. Kuittinen O., Savolainen E.R., Koistinen P., Turpeenniemi-Hujanen T. Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res. 1999, 19:4395-4400.
87. Ziober B.L., Turner M.A., Palefsky J.M. Type I collagen degradation by invasive oral squamous cell carcinoma. Oral Oncol. 2000, 36:365-372.
88. Kerkela E., Saarialho-Kere U. Matrix metalloproteinase in tumor progression: focus on basal and squamous cell skin cancer. Exp. Dermatol. 2003, 12:109-125.
89. Brinckerhoff C.E., Rutter J.L., Benbow U. Interstitial collagenases as marker of tumor progression. Clin. Cancer Res. 2000, 6:4823-4830.
90. Rutter J.L., Mitchell T.I., Buttice G., et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998, 58:5321-5325.
91. Tower G.B., Coon C.C., Benbow U., et al. Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim. Biophys. Acta 2002, 1586:265-274.
92. Chaudhary A.K., Pandya S., Mehrotra R., et al. Functional polymorphism of the MMP-1 promoter (-1607 1G/2G) in potentially malignant and malignant head and neck lesions in an Indian population. Biomarkers 2010, 15(8):684-692.
93. Nishizawa R., Nagata M., Noman A.A., et al. The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer 2007, 7:187.
94. Vairaktaris E., Yapijakis C., Vasiliou S., et al. Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Anticancer Res. 2007, 27:459-464.
95. Hashimoto T., Uchida K., Okayama N., et al. Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett. 2004, 211:19-24.
96. Cavalheiro B.G., Junqueira C.R., Brandão L.G. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: prognostic implications. Thyroid 2008, 18:865-871.
97. Malik M.A., Sharma K.L., Zargar S.A., Mittal B. Association of matrix metalloproteinase-7 (-181A>G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir Valley. Saudi J. Gastroenterol. 2011, 17:301-306.
98. Li Y., Sun D.L., Duan Y.N., et al. Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol. Biol. Rep. 2010, 37:197-205.
99. Vairaktaris E., Yapijakis C., Nkenke E., et al. A metalloproteinase-13 polymorphism affecting its gene expression is associated with advanced stages of oral cancer. Anticancer Res. 2007, 27:4027-4030.
100. Tu H.F., Liu C.J., Chang C.S., et al. The functional (-1171 5A-->6A) polymorphisms of matrix metalloproteinase 3 gene as a risk factor for oral submucous fibrosis among male areca users. J. Oral Pathol. Med. 2006, 35:99-103.
101. Lin S.C., Chung M.Y., Huang J.M., et al. Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J. Oral Pathol. Med. 2004, 33:323-326.
102. Bradbury P.A., Zhai R., Hopkins J., et al. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis 2009, 30:793-798.
103. Vairaktaris E., Vassiliou S., Nkenke E., et al. A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur. J. Surg. Oncol. 2008, 34:450-455.
104. Shimizu Y., Kondo S., Shirai A., et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer. Auris Nasus Larynx 2008, 35:381-389.
105. Nasr H.B., Mestiri S., Chahed K., et al. Matrix metalloproteinase-1 (-1607) 1G/2G and -9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas. Clin. Chim. Acta 2007, 384:57-63.
106. Tu H.F., Wu C.H., Kao S.Y., et al. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J. Oral Pathol. Med. 2007, 36:409-414.
107. O-charoenrat P., Leksrisakul P., Sangruchi S. A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int. J. Cancer 2006, 118:2548-2553.
108. O-Charoenrat P., Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol. 2006, 42:257-267.
109. Lin S.C., Lo S.S., Liu C.J., et al. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J. Oral Pathol. Med. 2004, 33:405-409.
110. Liu C.J., Chang K.W., Lin S.C., Cheng H.W. Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma. Oral Oncol. 2009, 45:920-925.
111. Liu Z., Li L., Yang Z., et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 2010, 10:270.
112. Wang X., Lu N., Niu B., Chen X., Xie J., Cheng N. Overexpression of Aurora-A enhances invasion and matrix metalloproteinase-2 expression in esophageal squamous cell carcinoma cells. Mol. Cancer Res. 2012, 10(5):588-596.
113. Lee S.Y., Park S.Y., Kim S.H., Choi E.C. Expression of matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the tonsil and their clinical significance. Clin. Exp. Otorhinolaryngol. 2011, 4:88-94.
114. Pradhan-Palikhe P., Vesterinen T., Tarkkanen J., et al. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer. Oral Oncol. 2010, 46:514-518.
115. Chuang H.C., Su C.Y., Huang H.Y., et al. Active matrix metalloproteinase-7 is associated with invasion in buccal squamous cell carcinoma. Mod. Pathol. 2008, 21:1444-1450.
116. de Vicente J.C., Lequerica-Fernández P., Santamaría J. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J. Oral Pathol. Med. 2007, 36:415-424.
117. Ruokolainen H., Pääkkö P., Turpeenniemi-Hujanen T. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma-tissue immunoreactivity predicts aggressive clinical course. Mod. Pathol. 2006, 19:208-217.
118. Ruokolainen H., Pääkkö P., Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin. Cancer Res. 2005, 11:3257-3264.
119. Gao Z.B., Duan Y.Q., Zhang L., et al. Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma. Int. J. Mol. Med. 2005, 16:599-603.
120. Liu S.Y., Lin M.H., Yang S.C., et al. Increased expression of matrix metalloproteinase-2 in oral cells after short-term stimulation and long-term usage of areca quid. J. Formos. Med. Assoc. 2005, 104:390-397.
121. Katayama A., Bandoh N., Kishibe K., et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin. Cancer Res. 2004, 10:634-640.
122. Krecicki T., Zalesska-Krecicka M., Jelen M., et al. Expression of type IV collagen and matrix metalloproteinase-2 (type IV collagenase) in relation to nodal status in laryngeal cancer. Clin. Otolaryngol. 2001, 26:469-472.
123. O-Charoenrat P., Rhys-Evans P.H., Eccles S.A. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2001, 127:813-820.
124. Park K.S., Kim S.J., Kim K.H., Kim J.C. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J. Gastroenterol. Hepatol. 2011, 26:391-397.
125. Fang W.L., Liang W.B., He H., Zhu Y., Li S.L., Gao L.B., Zhang L. Association of matrix metalloproteinases 1, 7, and 9 gene polymorphisms with genetic susceptibility to colorectal carcinoma in a Han Chinese population. DNA Cell Biol. 2010, 29:657-661.
126. Langenskiold M., Holmdahl L., Falk P., et al. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int. J. Colorectal Dis. 2005, 20:245-252.
127. Koskensalo S., Hagström J., Linder N., Lundin M., Sorsa T., Louhimo J., et al. Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer. BMC Clin. Pathol. 2012, 12:24.
128. Shi M., Yu B., Gao H., Mu J., Ji C. Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis. Mol. Biol. Rep. 2013, 40(1):617-623.
129. de Lima J.M., de Souza L.G., da Silva I.D., Forones N.M. E-cadherin and metalloproteinase-1 and -7 polymorphisms in colorectal cancer. Int. J. Biol. Markers 2009, 24:99-106.
130. Kouhkan F., Motovali-Bashi M., Hojati Z. The influence of interstitial collagenase-1 genotype polymorphism on colorectal cancer risk in Iranian population. Cancer Invest. 2008, 26:836-842.
131. Langers A.M., Sier C.F., Hawinkels L.J., et al. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br. J. Cancer 2008, 98:1820-1823.
132. Xing L.L., Wang Z.N., Jiang L., et al. Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J. Gastroenterol. 2007, 13:4626-4629.
133. Lièvre A., Milet J., Carayol J., et al. Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 2006, 6:270.
134. Zinzindohoué F., Lecomte T., Ferraz J.M., et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin. Cancer Res. 2005, 11:594-599.
135. Ghilardi G., Biondi M.L., Mangoni J., et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin. Cancer Res. 2001, 7:2344-2346.
136. Wang Y., Fang S., Wei L., et al. No association between the C-1562T polymorphism in the promoter of matrixmetalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer 2005, 49:155-161.
137. Hu Z., Huo X., Lu D., Qian J., Zhou J., Chen Y., et al. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin. Cancer Res. 2005, 11:5433-5439.
138. Zhang W.Q., Lin H., Zhou Y.A., et al. Association of MMP1-1607(1G>2G) single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006, 23:313-315.
139. González-Arriaga P., López-Cima M.F., Fernández-Somoano A., et al. Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk. BMC Cancer 2008, 8:378.
140. González-Arriaga P., Pascual T., García-Alvarez A., Fernández-Somoano A., López-Cima M.F., Tardón A. Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer 2012, 12:121.
141. Liu L., Wu J., Wu C., et al. A functional polymorphism (-1607 1G→2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer 2011, 117:5172-5181.
142. Bayramoglu A., Gunes H.V., Metintas M., et al. The association of MMP-9 enzyme activity, MMP-9 C1562T polymorphism, and MMP-2 and -9 and TIMP-1, -2, -3, and -4 gene expression in lung cancer. Genet Test. Mol. Biomarkers 2009, 13:671-678.
143. Jia J., Kang S., Zhao J. Association of functional polymorphisms on MMP-12 and MMP-13 gene promoter region with epithelial ovarian carcinoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2010, 27:209-213.
144. Li Y., Jia J.H., Kang S., et al. The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in Chinese. Int. J. Gynecol. Cancer 2009, 19:129-133.
145. Singh H., Jain M., Mittal B. MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer. Gynecol. Oncol. 2008, 110:71-75.
146. Baltazar-Rodriguez L.M., Anaya-Ventura A., Andrade-Soto M., et al. Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem. Genet. 2008, 46:137-144.
147. Li Y., Jin X., Kang S., et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol. Oncol. 2006, 101:92-96.
148. Ju W., Kang S., Kim J.W., et al. Promoter polymorphism in the matrix metalloproteinase-1 and risk of cervical cancer in Korean women. Cancer Lett. 2005, 217:191-196.
149. Szyllo K., Smolarz B., Romanowicz-Makowska H. The promoter polymorphism of the matrix metalloproteinase 3 (MMP-3) gene in women with ovarian cancer. J. Exp. Clin. Cancer Res. 2002, 21:357-361.
150. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 2000, 18:135-1149.
151. Betz M., Huxley P., Davies S.J., Mushtaq Y., Pieper M., Tschesche H., et al. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. J. Biochem. 1997, 247:356-363.
152. Macaulay V.M., O'Byrne K.J., Saunders M.P., Braybrooke J.P., Long L. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 1999, 5:513-520.
153. Davies B., Brown P.D., East N., Crimmin M.J., Balkwill F.R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993, 53(9):2087-2091.
154. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 2001, 93:178-193.
155. Wada N., Otani Y., Kubota T., Kimata M., Minagawa A., Yoshimizu N., et al. Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. Clin. Exp. Metastasis 2003, 20(5):431-435.
156. Wojtowicz-Praga S., Low J., Marshall J., Ness E., Dickson R., Barter J. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB94) in patients with advanced cancer. Invest. New Drugs 1996, 14:193-202.
157. Tierney G.M., Griffin N.R., Stuart R.C., Kasem H., Lynch K.P., Lury J.T. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur. J. Cancer 1999, 35(4):563-568.
158. North H., King J., Morris D.L. Effect of marimastat on serum tumour markers in patients with colorectal cancer. Int. J. Surg. Investig. 2000, 2(3):213-217.
159. Steward W.P. Marimastat (BB2516): current status of development. Cancer Chemother. Pharmacol. 1999, 43(Suppl.):S56-S60.
160. Zucker S., Wang M., Sparano J.A., Gradishar W.J., Ingle J.N., Davidson N.E. Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. Clin. Breast Cancer 2006, 6(6):525-529.
161. Wall L., Talbot D.C., Bradbury P., Jodrell D.I. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br. J. Cancer 2004, 90(4):800-804.
162. Bissett, Donald K., O'Byrne J., von Pawel J., Gatzemeier U., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. 2005, 10:909.
163. Rowinsky E.K., Humphrey R., Hammond L.A., et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. 2000, 18:178-186.
164. Hirte H., Vergote I.B., Jeffrey J.R., Grimshaw R.N., Coppieters S., Schwartz B., et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol. Oncol. 2006, 102(2):300-308.
165. Levitt N.C., Eskens F.A., O'Byrne K.J., Propper D.J., Denis L.J., Owen S.J. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin. Cancer Res. 2001, 7:1912-1922.
166. Boivin D., Gendron S., Beaulieu E., Gingras D., Béliveau R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol. Cancer Ther. 2002, 1(10):795-802.
167. Weber M.H., Lee J., Orr F.W. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int. J. Oncol. 2002, 20(2):299-303.
168. Syed S., Takimoto C., Hidalgo M., Rizzo J., Kuhn J.G., Hammond L.A., et al. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin. Cancer Res. 2004, 10(19):6512-6521.
169. Roy S.K., Kendrick D., Sadowitz B.D., Gatto L., Snyder K., Satalin J.M., et al. Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS). Pharmacol. Res. 2011, 64(6):580-589.
170. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 2009, 360(1):53-62.
171. Dedes P.G., Gialeli Ch., Tsonis A.I., Kanakis I., Theocharis A.D., et al. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim. Biophys. Acta 2012, 1820(12):1926-1939.